PPI meds are toxic with time and dose
2015-01-06 20:17:35 UTC
Long term maybe different, IMO and resulting in most osteoclasts and lower
bone density and lower bone quality. Alternately there is the other
theory more often repeated that this drug class weaken bones by slowing
remodeling. However in at least one study I aware of there was a decrease
in bone density which suggests the latter idea is wrong. Also this drug class impairs nutrient absorption and/or nutrient serum levels i.e. magnesium and vitamin B-12 (likely others as well) for additional
mechanisms for bone disease.
'''''''''''''''''''''''''''''''''''''
1. Gut Liver. 2014 Dec 5. doi: 10.5009/gnl14135. [Epub ahead of print]
A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study.
Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, SookPark Y, Kim HJ.
Background/Aims: Proton pump inhibitors (PPIs) act by irreversibly binding to the
H+-K+-ATPase of the proton pump in parietal cells and may possibly affect the
vacuolar H+-ATPase in osteoclasts.
Methods: We investigated the effect of 8 weeks of PPI treatment on the parameters
of bone turnover and compared PPI with revaprazan, which acts by reversibly
binding to H+-K+-ATPase in proton pumps. This study was a parallel randomized
controlled trial. For 8 weeks, either a PPI or revaprazan was randomly assigned
to patients with gastric ulcers. The parameters of bone turnover were measured at
the beginning of and after the 8-week treatment period.
Results: Twenty-six patients (PPI, n=13; revaprazan, n=13) completed the
intention-to-treat analysis. After the 8-week treatment period, serum calcium and
urine deoxypyridinoline (DPD) were increased in the PPI group (serum calcium,
p=0.046; urine DPD, p=0.046) but not in the revaprazan group. According to
multivariate linear regression analysis, age ≥60 years was an independent
predictor for the changes in serum calcium and urine DPD.
Conclusions: In elderly patients, administering a PPI for 8 weeks altered bone
parameters. Our study suggested that PPIs might directly alter bone metabolism
via the vacuolar H+-ATPase in osteoclasts. (Gut Liver, Published online December
5, 2014).
PMID: 25473078 [PubMed - as supplied by publisher]
Also note drug reps long denied this mechanism existed.
bone density and lower bone quality. Alternately there is the other
theory more often repeated that this drug class weaken bones by slowing
remodeling. However in at least one study I aware of there was a decrease
in bone density which suggests the latter idea is wrong. Also this drug class impairs nutrient absorption and/or nutrient serum levels i.e. magnesium and vitamin B-12 (likely others as well) for additional
mechanisms for bone disease.
'''''''''''''''''''''''''''''''''''''
1. Gut Liver. 2014 Dec 5. doi: 10.5009/gnl14135. [Epub ahead of print]
A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study.
Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, SookPark Y, Kim HJ.
Background/Aims: Proton pump inhibitors (PPIs) act by irreversibly binding to the
H+-K+-ATPase of the proton pump in parietal cells and may possibly affect the
vacuolar H+-ATPase in osteoclasts.
Methods: We investigated the effect of 8 weeks of PPI treatment on the parameters
of bone turnover and compared PPI with revaprazan, which acts by reversibly
binding to H+-K+-ATPase in proton pumps. This study was a parallel randomized
controlled trial. For 8 weeks, either a PPI or revaprazan was randomly assigned
to patients with gastric ulcers. The parameters of bone turnover were measured at
the beginning of and after the 8-week treatment period.
Results: Twenty-six patients (PPI, n=13; revaprazan, n=13) completed the
intention-to-treat analysis. After the 8-week treatment period, serum calcium and
urine deoxypyridinoline (DPD) were increased in the PPI group (serum calcium,
p=0.046; urine DPD, p=0.046) but not in the revaprazan group. According to
multivariate linear regression analysis, age ≥60 years was an independent
predictor for the changes in serum calcium and urine DPD.
Conclusions: In elderly patients, administering a PPI for 8 weeks altered bone
parameters. Our study suggested that PPIs might directly alter bone metabolism
via the vacuolar H+-ATPase in osteoclasts. (Gut Liver, Published online December
5, 2014).
PMID: 25473078 [PubMed - as supplied by publisher]
Also note drug reps long denied this mechanism existed.